Árbitros notifican laudo en la diferencia entre Türkiye y la Unión Europea relativa a los productos farmacéuticos
El 25 de julio de 2022, los árbitros distribuyeron a los Miembros de la OMC el laudo en el que habían examinado determinadas constataciones de la resolución del grupo especial de la OMC en la diferencia “Turquía — Determinadas medidas relativas a la producción, importación y comercialización de productos farmacéuticos” (DS583). Los tres árbitros fueron nombrados por Türkiye y la Unión Europea de conformidad con el artículo 25 del Entendimiento sobre Solución de Diferencias (ESD) de la OMC.
(de momento sólo en inglés)
The panel report was issued to the parties on a confidential basis on 11 November 2021. On 20 December 2021, the EU asked the panel to suspend its work and not to circulate its report. On 22 March 2022, the EU and Türkiye notified the WTO Dispute Settlement Body (DSB) that they had agreed on procedures for “arbitration under Article 25 of the DSU to decide any appeal from any final report” in this dispute. On 25 April 2022, Türkiye initiated arbitration to «appeal» certain panel findings, making public the final panel report as issued to parties.
The arbitrators recommended that Türkiye bring into conformity the measures that were found to be inconsistent in the award and in the panel report with its WTO obligations.
Parties entering into arbitration under Article 25 of the DSU agree to abide by the award, which shall be final. The award does not need to be adopted by the DSB.
Summary of key findings of Award
DS583: Turkey — Certain Measures Concerning the Production, Importation and Marketing of Pharmaceutical Products
